Cargando…

The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma

PURPOSE: Inter-tumoral heterogeneity at the differential lesion level raises the possibility of distinct organ-specific responses to immune checkpoint inhibitors (ICIs). We aimed to comprehensively examine the clinicopathological factors to predict and assess the efficacy of nivolumab, programmed ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Han Sang, Kim, Chang Gon, Hong, Jung Yong, Kim, Il-hwan, Kang, Beodeul, Jung, Sanghoon, Kim, Chan, Shin, Sang Joon, Choi, Hye Jin, Cheon, Jaekyung, Chon, Hong Jae, Lim, Ho Yeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290164/ https://www.ncbi.nlm.nih.gov/pubmed/35860833 http://dx.doi.org/10.1177/17588359221113266

Ejemplares similares

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
por: Cheon, Jaekyung, et al.
Publicado: (2023)

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
por: Kim, Chan, et al.
Publicado: (2022)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
por: Yang, Hannah, et al.
Publicado: (2023)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
por: Chon, Young Eun, et al.
Publicado: (2022)

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
por: Kim, Beom Kyung, et al.
Publicado: (2022)

High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma
por: Kim, Youngun, et al.
Publicado: (2023)

Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis
por: Cheon, Jaekyung, et al.
Publicado: (2021)

ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer
por: Lee, Sung Hwan, et al.
Publicado: (2023)

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
por: Sang, Yun Beom, et al.
Publicado: (2022)

STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
por: Lee, Seung Joon, et al.
Publicado: (2021)

Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway
por: Kim, Jeong Hun, et al.
Publicado: (2021)

High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer
por: Park, Hyung Soon, et al.
Publicado: (2021)

Effect of age on the prognosis of intrahepatic cholangiocarcinoma
por: Kim, Jung Hun, et al.
Publicado: (2023)

Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report
por: Cho, Hye Jung, et al.
Publicado: (2021)

Laparoscopic left hemihepatectomy for left intrahepatic duct stones
por: Jeong, Chi-Young, et al.
Publicado: (2012)

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma
por: Yu, Jeong Il, et al.
Publicado: (2019)

Prognosis after intrahepatic recurrence in the patients who underwent curative resection for hepatocellular carcinoma
por: Lee, Juhyeon, et al.
Publicado: (2020)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
por: Lee, Cheol-Hyung, et al.
Publicado: (2020)

Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?
por: Lee, Dong Ho, et al.
Publicado: (2021)

The effect of alkaline phosphatase and intrahepatic metastases in large hepatocellular carcinoma
por: Kim, Jong Man, et al.
Publicado: (2013)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020)

Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma
por: Park, Jongmoo, et al.
Publicado: (2018)

Clinical Efficacy of Hypofractionated Proton Beam Therapy for Intrahepatic Cholangiocarcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2022)

A Case of Clonorchiasis with Focal Intrahepatic Duct Dilatation Mimicking an Intrahepatic Cholangiocarcinoma
por: Kim, Bong Gap, et al.
Publicado: (2011)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
por: Kim, Hyung Jun, et al.
Publicado: (2023)

Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma
por: Kim, Young-Il, et al.
Publicado: (2013)

Characteristics of contrast-enhanced ultrasound in distinguishing small (≤3 cm) hepatocellular carcinoma from intrahepatic cholangiocarcinoma
por: Shin, Seung Kak, et al.
Publicado: (2018)

Percutaneous Radiofrequency Ablation with Multiple Electrodes for Medium-Sized Hepatocellular Carcinomas
por: Lee, Jung, et al.
Publicado: (2012)

Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation
por: Kim, Chang Gon, et al.
Publicado: (2019)

Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results
por: Kim, Ja Seon, et al.
Publicado: (2011)

Efficacy of Ultrasonography Guided Stellate Ganglion Blockade in the Stroke Patients with Complex Regional Pain Syndrome
por: Yoo, Seung Don, et al.
Publicado: (2012)

Complete regression of metastatic malignant melanoma endoscopically after nivolumab administration
por: Ryu, Dae Gon, et al.
Publicado: (2021)

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors
por: Lee, Keun‐Wook, et al.
Publicado: (2017)

Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report
por: Han, Ji Eun, et al.
Publicado: (2021)

Inadequate Ultrasound Examination in Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis
por: Hong, Seung Baek, et al.
Publicado: (2021)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

A Case of Hepatocellular Carcinoma Within Hepatocellular Adenoma in a Non-Cirrhotic Male
por: Kim, Dong Hwan, et al.
Publicado: (2009)

Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification
por: Sang, Yun Beom, et al.
Publicado: (2023)

Association between insulin resistance, hyperglycemia, and coronary artery disease according to the presence of diabetes
por: Cho, Young-Rak, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vooub7jkp8rjol863qj6ine6bi